• Prisca A Oria, Wycliffe Matini, Ian Nelligan, Gideon Emukule, Martha Scherzer, Beryl Oyier, Hezron N Ochieng, Laura Hooper, Anne Kanyuga, Phillip Muthoka, Kathleen F Morales, Charles Nzioka, Robert F Breiman, and Mark A Katz.
• Kenya Medical Research Institute/Centers for Disease Control and Prevention-Kenya (KEMRI/CDC-Kenya), Nairobi, Kenya. poria@ke.cdc.gov
• Vaccine. 2011 Apr 27; 29 (19): 3617-22.

AbstractOver 1200 cases of 2009 pandemic influenza A H1N1 (pH1N1) have been identified in Kenya since the first case in June 2009. In April 2010 the Kenyan government launched a program to immunize high-risk groups and healthcare workers (HCWs) with pH1N1 vaccines donated by the World Health Organization. To characterize HCWs' knowledge, attitudes and practices regarding pH1N1 vaccination, we conducted a quantitative and qualitative survey in 20 healthcare facilities across Kenya between January 11 and 26, 2010. Of 659 HCWs interviewed, 55% thought there was a vaccine against pH1N1, and 89% indicated that they would receive pH1N1 vaccine if it became available. In focus group discussions, many HCWs said that pH1N1 virus infection did not cause severe disease in Kenyans and questioned the need for vaccination. However, most were willing to accept vaccination if they had adequate information on safety and efficacy. In order for the influenza vaccination campaign to be successful, HCWs must understand that pH1N1 can cause severe disease in Kenyans, that pH1N1 vaccination can prevent HCWs from transmitting influenza to their patients, and that the vaccine has been widely used globally with few recognized adverse events.Copyright © 2011 Elsevier Ltd. All rights reserved.

27 keywords...

hide…